{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T09:21:50Z","timestamp":1774084910389,"version":"3.50.1"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,3,1]],"date-time":"2016-03-01T00:00:00Z","timestamp":1456790400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"CodonMedical"},{"name":"XenoPort, Inc"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","sleep-journal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Sleep Medicine"],"published-print":{"date-parts":[[2016,3]]},"DOI":"10.1016\/j.sleep.2015.11.002","type":"journal-article","created":{"date-parts":[[2015,11,14]],"date-time":"2015-11-14T08:17:14Z","timestamp":1447489034000},"page":"50-56","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Efficacy of gabapentin enacarbil in adult patients with severe primary restless legs syndrome"],"prefix":"10.1016","volume":"19","author":[{"given":"Daniel O.","family":"Lee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark J.","family":"Buchfuhrer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diego","family":"Garcia-Borreguero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alon Y.","family":"Avidan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mansoor","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryan","family":"Hays","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William G.","family":"Ondo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark J.","family":"Jaros","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gwendoline","family":"Shang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.sleep.2015.11.002_bib0010","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.sleep.2014.03.025","article-title":"Restless legs syndrome\/Willis-Ekbom disease diagnostic criteria: updated International Restless Legs Syndrome Study Group (IRLSSG) consensus criteria\u2014 \u2013 history, rationale, description, and significance","volume":"15","author":"Allen","year":"2014","journal-title":"Sleep Med"},{"key":"10.1016\/j.sleep.2015.11.002_bib0015","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1001\/archinte.165.11.1286","article-title":"Restless legs syndrome prevalence and impact: REST general population study","volume":"165","author":"Allen","year":"2005","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.sleep.2015.11.002_bib0020","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1001\/archinte.164.2.196","article-title":"Sex and the risk of restless legs syndrome in the general population","volume":"164","author":"Berger","year":"2004","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.sleep.2015.11.002_bib0025","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.smrv.2011.05.002","article-title":"Epidemiology of restless legs syndrome: a synthesis of the literature","volume":"16","author":"Ohayon","year":"2012","journal-title":"Sleep Med Rev"},{"key":"10.1016\/j.sleep.2015.11.002_bib0030","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.sleep.2010.12.018","article-title":"Prevalence of restless legs syndrome in North American and Western European populations: a systematic review","volume":"12","author":"Innes","year":"2011","journal-title":"Sleep Med"},{"key":"10.1016\/j.sleep.2015.11.002_bib0035","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S1389-9457(02)00258-7","article-title":"Validation of the International Restless Legs Syndrome Study Group rating scale for restless legs syndrome","volume":"4","author":"Walters","year":"2003","journal-title":"Sleep Med"},{"key":"10.1016\/j.sleep.2015.11.002_bib0040","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.sleep.2005.03.008","article-title":"Prevalence, severity and risk factors of restless legs syndrome in the general adult population in two Scandinavian countries","volume":"6","author":"Bjorvatn","year":"2005","journal-title":"Sleep Med"},{"key":"10.1016\/j.sleep.2015.11.002_bib0045","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1212\/01.WNL.0000163996.64461.A3","article-title":"Restless legs syndrome: a community-based study of prevalence, severity, and risk factors","volume":"64","author":"H\u00f6gl","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.sleep.2015.11.002_bib0050","doi-asserted-by":"crossref","first-page":"e94821","DOI":"10.1371\/journal.pone.0094821","article-title":"Effects of short- and long-term variations in RLS severity on perceived health status \u2013 the COR-study","volume":"9","author":"Fuhs","year":"2014","journal-title":"PLoS ONE"},{"key":"10.1016\/j.sleep.2015.11.002_bib0055","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.sleep.2004.01.006","article-title":"Subjective and objective criteria in the diagnosis of the restless legs syndrome","volume":"5","author":"Hening","year":"2004","journal-title":"Sleep Med"},{"key":"10.1016\/j.sleep.2015.11.002_bib0060","series-title":"Horizant [prescribing information]","year":"2013"},{"key":"10.1016\/j.sleep.2015.11.002_bib0065","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.sleep.2013.05.016","article-title":"The long-term treatment of restless legs syndrome\/Willis-Ekbom disease: evidence based guidelines and clinical consensus best practice guidance: a report from the International Restless Legs Syndrome Study Group","volume":"14","author":"Garcia-Borreguero","year":"2013","journal-title":"Sleep Med"},{"key":"10.1016\/j.sleep.2015.11.002_bib0070","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1001\/archneur.61.9.1393","article-title":"Long-term treatment of restless legs syndrome with dopamine agonists","volume":"61","author":"Ondo","year":"2004","journal-title":"Arch Neurol"},{"key":"10.1016\/j.sleep.2015.11.002_bib0075","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.sleep.2003.07.005","article-title":"Augmentation and tolerance with long-term pramipexole treatment of restless legs syndrome (RLS)","volume":"5","author":"Winkelman","year":"2004","journal-title":"Sleep Med"},{"key":"10.1016\/j.sleep.2015.11.002_bib0080","first-page":"81","article-title":"Impulse control disorders with the use of dopaminergic agents in restless legs syndrome: a case-control study","volume":"33","author":"Cornelius","year":"2010","journal-title":"Sleep"},{"key":"10.1016\/j.sleep.2015.11.002_bib0085","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/1471-2377-11-28","article-title":"Algorithms for the diagnosis and treatment of restless legs syndrome in primary care","volume":"11","author":"Garcia-Borreguero","year":"2011","journal-title":"BMC Neurol"},{"key":"10.1016\/j.sleep.2015.11.002_bib0090","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1124\/jpet.104.067959","article-title":"XP13512 [(+\/-)-1-([(alpha-isobutanoyloxyethoxy)carbonyl] aminomethyl)-1-cyclohexane acetic acid], a novel gabapentin prodrug: II. Improved oral bioavailability, dose proportionality, and colonic absorption compared with gabapentin in rats and monkeys","volume":"311","author":"Cundy","year":"2004","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.sleep.2015.11.002_bib0095","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1177\/0091270008322909","article-title":"Clinical pharmacokinetics of XP13512, a novel transported prodrug of gabapentin","volume":"48","author":"Cundy","year":"2008","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.sleep.2015.11.002_bib0100","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1212\/01.wnl.0000341770.91926.cc","article-title":"Randomized, double-blind, placebo-controlled study of XP13512\/GSK1838262 in patients with RLS","volume":"72","author":"Kushida","year":"2009","journal-title":"Neurology"},{"key":"10.1016\/j.sleep.2015.11.002_bib0105","doi-asserted-by":"crossref","first-page":"282","DOI":"10.3390\/jcm7090282","article-title":"A randomized, double-blind, placebo-controlled study to assess the efficacy and tolerability of gabapentin enacarbil in subjects with restless legs syndrome","volume":"7","author":"Lee","year":"2011","journal-title":"J Clin Sleep Med"},{"key":"10.1016\/j.sleep.2015.11.002_bib0110","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1097\/WNF.0b013e318259eac8","article-title":"A randomized, double-blind, placebo-controlled, dose-response study to assess the pharmacokinetics, efficacy, and safety of gabapentin enacarbil in subjects with restless legs syndrome","volume":"35","author":"Lal","year":"2012","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.sleep.2015.11.002_bib0115","doi-asserted-by":"crossref","first-page":"31","DOI":"10.2147\/JPRLS.S40804","article-title":"Gabapentin enacarbil in subjects with moderate to severe primary restless legs syndrome with and without severe sleep disturbance: an integrated analysis of subjective and novel sleep endpoints from two studies","volume":"3","author":"Bogan","year":"2013","journal-title":"J Parkinsonism Restless Legs Syndr"},{"key":"10.1016\/j.sleep.2015.11.002_bib0120","doi-asserted-by":"crossref","DOI":"10.3109\/07853890.2015.1025825","article-title":"Treatment response to sleep, pain, and mood disturbance and their correlation with sleep disturbance in adult patients with moderate-to-severe primary restless legs syndrome: pooled analyses from 3 trials of gabapentin enacarbil","author":"Bogan","year":"2015","journal-title":"Ann Med"},{"key":"10.1016\/j.sleep.2015.11.002_bib0125","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1097\/WNF.0b013e3181b3ab16","article-title":"Gabapentin enacarbil in restless legs syndrome: a phase 2b, 2-week, randomized, double-blind, placebo-controlled trial","volume":"32","author":"Walters","year":"2009","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.sleep.2015.11.002_bib0130","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1016\/j.clinthera.2013.06.016","article-title":"Ropinirole in patients with restless legs syndrome and baseline IRLS total scores \u2265 24: efficacy and tolerability in a 26-week, double-blind, parallel-group, placebo-controlled study followed by a 40-week open-label extension","volume":"35","author":"Giorgi","year":"2013","journal-title":"Clin Ther"},{"key":"10.1016\/j.sleep.2015.11.002_bib0135","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1185\/030079906X132442","article-title":"Efficacy and tolerability of ropinirole in patients with restless legs syndrome and a baseline IRLS total score \u2265 24 points \u2013 data from the ropinirole clinical trial programme","volume":"22","author":"Giorgi","year":"2006","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.sleep.2015.11.002_bib0140","first-page":"28","article-title":"The clinical global impressions scale: applying a research tool in clinical practice","volume":"4","author":"Busner","year":"2007","journal-title":"Psychiatry (Edgmont)"},{"key":"10.1016\/j.sleep.2015.11.002_bib0145","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/1471-2377-11-48","article-title":"Validation of the post sleep questionnaire for assessing subjects with restless legs syndrome: results from two double-blind, multicenter, placebo-controlled clinical trials","volume":"11","author":"Canafax","year":"2011","journal-title":"BMC Neurol"},{"key":"10.1016\/j.sleep.2015.11.002_bib0150","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1037\/1040-3590.7.1.80","volume":"7","author":"Curran","year":"1995","journal-title":"Psychol Assess"},{"key":"10.1016\/j.sleep.2015.11.002_bib0155","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1111\/j.1524-4733.2005.03010.x","article-title":"Validation of the Restless Legs Syndrome Quality of Life questionnaire","author":"Abetz","year":"2005","journal-title":"Value Health"},{"key":"10.1016\/j.sleep.2015.11.002_bib0160","series-title":"Handbook of pain assessment","first-page":"135","article-title":"Self-report scales and procedures for assessing pain in adults","author":"Jensen","year":"1992"},{"key":"10.1016\/j.sleep.2015.11.002_bib0165","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.pain.2005.09.033","article-title":"Categorising the severity of neck pain: establishment of cut points for use in clinical and epidemiological research","volume":"119","author":"Fejer","year":"2005","journal-title":"Pain"},{"key":"10.1016\/j.sleep.2015.11.002_bib0170","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/0304-3959(94)00178-H","article-title":"When is cancer pain mild, moderate or severe? Grading pain severity by its interference with function","volume":"61","author":"Serlin","year":"1995","journal-title":"Pain"},{"key":"10.1016\/j.sleep.2015.11.002_bib0175","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.pain.2005.01.028","article-title":"Identification of cut-points for mild, moderate and severe pain due to diabetic peripheral neuropathy","volume":"115","author":"Zelman","year":"2005","journal-title":"Pain"},{"key":"10.1016\/j.sleep.2015.11.002_bib0180","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S0304-3959(01)00349-9","article-title":"Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale","volume":"94","author":"Farrar","year":"2001","journal-title":"Pain"},{"key":"10.1016\/j.sleep.2015.11.002_bib0185","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.sleep.2004.03.006","article-title":"Impact, diagnosis and treatment of restless legs syndrome (RLS) in a primary care population: the REST (RLS epidemiology, symptoms, and treatment) primary care study","volume":"5","author":"Hening","year":"2004","journal-title":"Sleep Med"},{"key":"10.1016\/j.sleep.2015.11.002_bib0190","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.sleep.2014.12.024","article-title":"Prevalance and clinical characteristics of patients with restless legs syndrome with painful symptoms","volume":"16","author":"Cho","year":"2015","journal-title":"Sleep Med"},{"key":"10.1016\/j.sleep.2015.11.002_bib0195","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s11940-014-0317-2","article-title":"Restless legs syndrome: pathophysiology and treatment","volume":"16","author":"Ondo","year":"2015","journal-title":"Curr Treat Options Neurol"},{"key":"10.1016\/j.sleep.2015.11.002_bib0200","doi-asserted-by":"crossref","first-page":"249","DOI":"10.2147\/NDT.S30160","article-title":"Gabapentin enacarbil for the treatment of moderate to severe primary restless legs syndrome (Willis-Ekbom disease): 600 or 1,200\u2009mg dose?","volume":"10","author":"Kume","year":"2014","journal-title":"Neuropsychiatr Dis Treat"},{"key":"10.1016\/j.sleep.2015.11.002_bib0205","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1002\/mds.23771","article-title":"Randomized polysomnography study of gabapentin enacarbil in subjects with restless legs syndrome","volume":"26","author":"Winkelman","year":"2011","journal-title":"Mov Disord"},{"key":"10.1016\/j.sleep.2015.11.002_bib0210","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.pnpbp.2011.10.009","article-title":"Long-term efficacy and safety of gabapentin enacarbil in Japanese restless legs syndrome patients","volume":"36","author":"Inoue","year":"2012","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.sleep.2015.11.002_bib0215","doi-asserted-by":"crossref","first-page":"773","DOI":"10.2165\/11634870-000000000-00000","article-title":"Dose response of gabapentin enacarbil versus placebo in subjects with moderate-to-severe primary restless legs syndrome: an integrated analysis of three 12-week studies","volume":"26","author":"VanMeter","year":"2012","journal-title":"CNS Drugs"},{"key":"10.1016\/j.sleep.2015.11.002_bib0220","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1185\/03007995.2012.746217","article-title":"Gabapentin enacarbil in Japanese patients with restless legs syndrome: a 12-week, randomized, double-blind, placebo-controlled, parallel-group study","volume":"29","author":"Inoue","year":"2013","journal-title":"Curr Med Res Opin"}],"container-title":["Sleep Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1389945715020328?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1389945715020328?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T11:05:29Z","timestamp":1567335929000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1389945715020328"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3]]},"references-count":43,"alternative-id":["S1389945715020328"],"URL":"https:\/\/doi.org\/10.1016\/j.sleep.2015.11.002","relation":{},"ISSN":["1389-9457"],"issn-type":[{"value":"1389-9457","type":"print"}],"subject":[],"published":{"date-parts":[[2016,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy of gabapentin enacarbil in adult patients with severe primary restless legs syndrome","name":"articletitle","label":"Article Title"},{"value":"Sleep Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.sleep.2015.11.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2015 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}